Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Nesina (alogliptin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• This summary is based on the review of five systematic review(s)/meta-analysis(es). ^[1-5]
• Adherence and Discontinuation: Adherence to alogliptin was indicated by a medication possession ratio (MPR) ranging from 61.7% to 94.9%. Within 12 months, 29%-44% of subjects on SGLT2 inhibitors (including drugs other than alogliptin) discontinued treatment.
• Renal Outcomes: No significant difference in the rate of change in eGFR or in the progression of albuminuria was observed between DPP4 inhibitors, including alogliptin, and the control groups.
• Cardiovascular Outcomes: DPP4 inhibitors, including alogliptin, were not associated with an increased risk of major cardiovascular events (MACE), all-cause mortality, or heart failure, except saxagliptin, which had an increased risk of heart failure.
• The risk of adverse events (AEs) for DPP4 inhibitors, including alogliptin, was similar to placebo both within 52 weeks (RR 0.93) and beyond 52 weeks (RR 0.98), with no significant increase in all-cause mortality (RR 1.04).
• No significant increase in the incidence of hypoglycemia and upper respiratory tract infection (URTI) was reported for DPP4 inhibitors, including alogliptin, compared to other drugs, with vildagliptin and sitagliptin showing slightly lower probabilities for these specific AEs.
• There is no population types or subgroups information available in the reviewed studies.